FrancophonIA/ELRC3.0 huggingface dataset:
English: Cholestagel should not be used in people who may be hypersensitive (allergic) to colesevelam or any of the other ingredients.
Estonian: Cholestagelit ei tohi kasutada patsiendid, kes võivad olla kolesevelaami või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Blood cholesterol levels should also be measured before and during treatment to check the patient's response.
Estonian: Vere kolesteroolisisaldust tuleb mõõta enne ravi ja ravi ajal, hinnates nii patsiendi ravivastust.
English: • as an add-on to a cholesterol-lowering diet, to reduce total-cholesterol and LDL-cholesterol levels in patients who cannot take statins;
Estonian: • lisandina kolesterooli vähendavale dieedile, et vähendada kogu kolesteroolisisaldust ja LDLkolesteroolisisaldust patsientidel, kes ei saa võtta statiine;
English: Other information about Cholestagel:
Estonian: Muu teave Cholestageli kohta
English: They can either be taken all at once, or split into two doses during the day.
Estonian: Tabletid võib võtta kõik korraga või jagatuna kaheks annuseks ööpäevas.
English: The active substance in Cholestagel, colesevelam, is not absorbed by the body, but stays in the gut, where it attaches to substances called bile acids and carries them out of the body in the faeces.
Estonian: Cholestageli toimeaine kolesevelaam ei imendu organismis, vaid püsib sooles, kus seondub sapphapetega ja kannab need roojaga organismist välja.
English: Three of these studies looked at Cholestagel taken in combination with a statin (lovastatin, simvastatin or atorvastatin) in 491 patients, two looked at Cholestagel taken on its own in 592 patients, and one looked at Cholestagel in combination with ezetimibe in 86 patients.
Estonian: Nendest kolmes uuringus uuriti Cholestageli kasutamist koos teatud statiiniga (lovastatiini, simvastatiini või atorvastatiiniga) 491 patsiendil, kahes uuringus uuriti Cholestageli kasutamist ainsa ravimina 592 patsiendil ning ühes uuringus uuriti Cholestageli kasutamist koos esetimiibiga 86 patsiendil.
English: The maximum dose is seven tablets a day when it is taken on its own, and six tablets a day when it is taken with other medicines.
Estonian: Suurim annus on 7 tabletti ööpäevas, kui ravimit kasutatakse ainsa ravimina, ja 6 tabletti ööpäevas, kui ravimit kasutatakse koos teiste ravimitega.
English: Why has Cholestagel been approved?
Estonian: Miks Cholestagel heaks kiideti?
English: Cholestagel is a medicine that contains the active substance colesevelam.
Estonian: Cholestagel on ravim, mis sisaldab toimeainena kolesevelaami.
English: The recommended dose of Cholestagel is six tablets a day when it is taken on its own, and four to six tablets a day when it is taken in combination with other medicines.
Estonian: Cholestageli soovituslik annus on 6 tabletti ööpäevas, kui seda võetakse eraldi, ja 4-6 tabletti ööpäevas, kui seda võetakse koos teiste ravimitega.
English: The combination of Cholestagel and ezetimibe was more effective than ezetimibe taken with placebo: there was a fall of 32% in LDL-cholesterol levels in the patients taking Cholestagel and a fall of 21% in those taking placebo.
Estonian: Cholestageli ja esetimiibi kombinatsioon oli efektiivsem kui esetimiibi ja platseebo kombinatsioon: Cholestagelit võtnud patsientidel vähenes LDL-kolesterooli sisaldus 32% ja platseebot saanud patsientidel 21%.
English: What is the risk associated with Cholestagel?
Estonian: Mis riskid Cholestageliga kaasnevad?
English: It must not be used in patients whose gut or bile duct is blocked.
Estonian: Ravimit ei tohi kasutada patsiendid, kellel on soole- või sapijuhaummistus.
English: Cholestagel colesevelam
Estonian: Cholestagel kolesevelaam
English: In studies, the most common side effects with Cholestagel (seen in more than 1 patient in 10) were flatulence (gas) and constipation.
Estonian: Cholestageli kõige sagedamad kõrvalnähud uuringutes (esinenud enam kui 1 patsiendil 10st) olid kõhupuhitus ja kõhukinnisus.
English: ‘Primary' means that there is no disease causing the high cholesterol levels.
Estonian: Primaarne tähendab, et suurt kolesteroolisisaldust ei põhjusta muu haigus.
English: What is Cholestagel?
Estonian: Mis on Cholestagel?
English: Cholestagel is used to lower cholesterol levels in adults with primary hypercholesterolaemia (high blood cholesterol levels).
Estonian: Cholestagelit kasutatakse vere kolesteroolisisalduse vähendamiseks täiskasvanuil, kellel on primaarne hüperkolesteroleemia (suur kolesteroolisisaldus veres).
English: The main measure of effectiveness was the decrease in LDL-cholesterol levels after four to six weeks, except for one of the studies looking at Cholestagel taken on its own, which measured the cholesterol levels after six months.
Estonian: Efektiivsuse põhinäitaja oli LDL-kolesterooli sisalduse vähenemine 4-6 nädala järel, v.a uuring, milles uuriti Cholestageli kasutamist ainsa ravimina: selles uuringus mõõdeti kolesterooli sisaldust 6 kuu järel.
English: The final study looked at Cholestagel as an add-on to ezetimibe and a statin in 86 adults with familial hypercholesterolaemia.
Estonian: Viimases uuringus uuriti Cholestageli lisamist esetimiibile ja teatud statiinile 86 täiskasvanul, kellel oli familiaalne hüperkolesteroleemia.
English: Cholestagel has been compared with placebo (a dummy treatment) in seven main studies involving adults with primary hypercholesterolaemia.
Estonian: Cholestagelit võrreldi platseeboga (näiv ravim) seitsmes põhiuuringus, milles osalesid primaarse hüperkolesteroleemiaga täiskasvanud patsiendid.
English: For the full list of all side effects reported with Cholestagel, see the Package Leaflet.
Estonian: Cholestageli kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: In comparison, the patients taking placebo had no changes in LDL-cholesterol levels.
Estonian: Seevastu platseebot (näiv ravim) saanud patsientidel LDL-kolesterooli sisaldus ei muutunud.
English: As the liver uses cholesterol to make bile acids, this reduces cholesterol levels in the blood.
Estonian: Maks kasutab sapphapete tekitamiseks kolesterooli, mis vähendab kolesterooli sisaldust veres.
English: When added to ezetimibe and a statin, Cholestagel caused a reduction of 11% in LDL-cholesterol levels after six weeks in patients with familial hypercholesterolaemia, compared with a rise of 7% when adding placebo.
Estonian: Esetimiibile ja teatud statiinile lisatud Cholestagel vähendas 6 nädala pärast familiaalse hüperkolesteroleemiaga patsientidel LDL-kolesterooli sisaldust 11%, kuid platseebo lisamine suurendas kolesterooli sisaldust 7%.
English: Looking at the results of the three studies in which Cholestagel was used with a statin, there was an 8% reduction in LDL-cholesterol levels with 2.3 g Cholestagel (about four tablets) after six weeks, as compared to placebo.
Estonian: Kolmes uuringus, kus Cholestagelit kasutati koos teatud statiiniga, vähenes 6 nädala pärast LDLkolesterooli sisaldus 2,3 g Cholestageli (ligikaudu neli tabletti) võtmisel 8% võrrelduna platseeboga.
English: What benefit has Cholestagel shown during the studies?
Estonian: Milles seisneb uuringute põhjal Cholestageli kasulikkus?
English: • as an add-on to a statin (another cholesterol-lowering medicine) and a cholesterol-lowering diet, to further reduce ‘low-density-lipoprotein' (LDL or ‘bad') cholesterol levels in patients who are not adequately controlled with a statin alone;
Estonian: • teatud statiini (teine kolesterooli sisaldust vähendav ravim) lisandina ja kolesterooli vähendava dieedi lisaravimina LDL-kolesteroolisisalduse vähendamiseks patsientidel, kelle kolesteroolisisaldus ravile ainult statiiniga ei allu;
English: How does Cholestagel work?
Estonian: Kuidas Cholestagel toimib?
English: What is Cholestagel used for?
Estonian: Milleks Cholestagelit kasutatakse?
English: In the studies looking at Cholestagel taken on its own, more than half of the patients receiving 3.8 or 4.5 g Cholestagel (about six to seven tablets) had a decrease in LDL-cholesterol level of 15 to 18% after six weeks.
Estonian: Uuringutes, milles uuriti Cholestageli manustamist ainsa ravimina, vähenes Cholestagelit 3,8 või 4,5 g (ligikaudu 6-7 tabletti) võtnud patsientidel LDL-kolesterooli sisaldus 6 nädala pärast 15-18%.
English: The full EPAR for Cholestagel can be found here.
Estonian: Euroopa avaliku hindamisaruande täistekst Cholestageli kohta on siin.
English: How is Cholestagel used?
Estonian: Kuidas Cholestagelit kasutatakse?
English: Because the bile acids are prevented from being absorbed into the bloodstream, the liver is forced to make more bile acids.
Estonian: Et see takistab sapphapete sattumist verre, tekib maksas sapphappeid rohkem.
English: How has Cholestagel been studied?
Estonian: Kuidas Cholestagelit uuriti?
English: In the longer study, the decrease seen at six weeks with 3.8 g Cholestagel (about six tablets) was maintained for six months.
Estonian: Pikaajalisemas uuringus täheldati, et 3,8 g Cholestagelit (ligikaudu 6 tabletti) võtnud patsientidel püsis 6 nädalaga vähenenud kolesteroolisisaldus 6 kuud.
English: There was a 16% reduction with 3.8 g Cholestagel (about six tablets).
Estonian: 3,8 g Cholestageli (ligikaudu 6 tabletti) manustamisel vähenes kolesterooli sisaldus 16% võrra.
English: For more information about treatment with Cholestagel, read the Package Leaflet (also part of the EPAR).
Estonian: Ravimi kasutamise üksikasjalik teave on pakendi infolehel, mis on samuti Euroopa avaliku hindamisaruande osa.
English: Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Estonian: IV lisa Teaduslikud järeldused ja müügilubade tingimuste muutmise alused ning ravimiohutuse riskihindamise nõuandekomitee soovitusest lahknemise teaduslike aluste üksikasjalikud selgitused
English: The applicant requested a re-examination of the opinion.
Estonian: Taotleja taotles arvamuse uuesti läbivaatamist.
English: They noted that the genotoxicity data (the potential for the substance to damage genes) showed differences from that for other antibiotics in the same class, and that the reasons for these differences were unclear.
Estonian: Komitee märkis, et andmetes genotoksilisuse kohta (aine geenekahjustav toime) ilmnes erinevusi teiste sama klassi antibiootikumidega võrreldes ning et nende erinevuste põhjused ei olnud selged.
English: After having considered the grounds for this request, the CVMP re-examined the initial opinion, and confirmed the recommendation of the refusal of the marketing authorisation application on 14 September 2006.
Estonian: Pärast selle taotluse põhjenduste läbivaatamist vaatas veterinaarravimite komitee algse arvamuse uuesti läbi ja kinnitas 14. septembril 2006. aastal antud soovitust keelduda müügiloa andmisest.
English: For this reason the Committee concluded that the safety of pradofloxacin had not been conclusively proven.
Estonian: Komitee otsustas seepärast, et pradofloksatsiini ohutust ei olnud veenvalt tõestatud.
English: The company who applied for a marketing authorisation is Bayer HealthCare AG.
Estonian: Müügiluba taotles ettevõte Bayer HealthCare AG.
English: International Non-proprietary Name (INN): pradofloxacin
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): pradofloksatsiin
English: This results in the bacteria dying and so the infection is cured.
Estonian: Selle tulemusena bakterid hävivad ja infektsioon paraneb.
English: What documentation did the Company present to support its application to the CVMP?
Estonian: Millised dokumendid esitas ettevõte veterinaarravimite komiteele oma taotluse toetuseks?
English: On 17 May 2006 the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Veraflox 15 mg, 60 mg & 120 mg Tablets for Cats and Dogs, and Veraflox 25 mg/ml Oral Suspension for Cats.
Estonian: 17. mail 2006 võttis veterinaarravimite komitee vastu eitava otsuse, soovitades keelduda müügiloa andmisest tablettravimile Veraflox 15 mg, 60 mg ja 120 mg kassidele ja koertele ning suukaudsele suspensioonile Veraflox 25 mg/ml kassidele.
English: Like other antibiotics, pradofloxacin is not effective against every type of bacteria.
Estonian: Nagu teisedki antibiootikumid, ei mõju pradofloksatsiin igat liiki bakteritele.
English: The CVMP was therefore of the opinion that Veraflox's benefits had not been shown to be greater than its risks.
Estonian: Seega leidis veterinaarravimite komitee, et ei olnud tõestatud, et Verafloxi kasulikkus on suurem kui sellega kaasnevad riskid.
English: Veraflox is an antibiotic.
Estonian: Veraflox on antibiootikum.
English: The CVMP considered that the company had not been able to identify a dose that was effective whilst at the same time providing an adequate margin of safety.
Estonian: Veterinaarravimite komitee leidis, et ettevõte ei olnud määranud kindlaks efektiivset, aga samas piisava ohutusvaruga annust.
English: In all studies the effectiveness of Veraflox was compared to antibiotics which are commonly used for the treatment of the infection studied.
Estonian: Kõikides uuringutes võrreldi Verafloxi efektiivsust antibiootikumidega, mida kasutatakse uuritud infektsiooni ravimiseks tavaliselt.
English: What is Veraflox?
Estonian: Mis on Veraflox?
English: No adverse consequences for animals have been identified by the CVMP, as other medicines exist for all the infections in cats and dogs which Veraflox was intended to treat.
Estonian: Veterinaarravimite komitee ei leidnud kahjulikke tagajärgi loomadele, sest koerte ja kasside kõikide infektsioonide ravimiseks, milleks kavatseti kasutada Verafloxi, on olemas teisi ravimeid.
English: Which were the major concerns that lead the CVMP to recommend the refusal of a marketing authorisation?
Estonian: Millised olid peamised probleemid, mille tõttu veterinaarravimite komitee soovitas müügiloa andmisest keelduda?
English: All these fluoroquinolones, including pradofloxacin, kill bacteria by interacting with some of the enzymes in bacteria responsible for major DNA functions.
Estonian: Kõik fluorokinoloonid, sealhulgas pradofloksatsiin, hävitavad baktereid nende teatavate ensüümide mõjutamise teel, millest olenevad põhilised DNA-funktsioonid.
English: QUESTIONS AND ANSWERS ON THE RECOMMENDATION FOR REFUSAL OF A MARKETING AUTHORISATION APPLICATION for VERAFLOX
Estonian: TEAVE SOOVITUSE KOHTA KEELDUDA VÄLJASTAMAST MÜÜGILUBA ravimile VERAFLOX
English: Veraflox Oral Suspension contains 25 mg/ml pradofloxacin.
Estonian: Verafloxi suukaudne suspensioon sisaldab 25 mg/ml pradofloksatsiini.
English: What are the consequences for animals of the refusal for Veraflox?
Estonian: Millised on Verafloxile müügiloa andmisest keeldumise tagajärjed loomadele?
English: Veraflox Tablets contain 15 mg, 60 mg & 120 mg of the active substance, pradofloxacin.
Estonian: Verafloxi tablett sisaldab 15 mg, 60 mg või 120 mg toimeainet pradofloksatsiini.
English: The active substance in Veraflox, pradofloxacin, belongs to a class of antibiotics called third generation fluoroquinolones.
Estonian: Verafloxi toimeaine pradofloksatsiin on antibiootikum, mis kuulub kolmanda põlvkonna fluorokinoloonide hulka.
English: How is Veraflox expected to work?
Estonian: Milline on Verafloxi eeldatav toime?
English: The company presented the results of studies examining the effectiveness of Veraflox against a range of conditions involving bacterial infections in cats and dogs.
Estonian: Ettevõte esitas uuringute tulemused Verafloxi efektiivsuse kohta mitmesuguste seisundite puhul, sealhulgas koerte ja kasside bakteriaalsed infektsioonid.
English: Hence, the CVMP recommended that Veraflox be refused a marketing authorisation.
Estonian: Veterinaarravimite komitee soovitas seepärast keelduda andmast Verafloxile müügiluba.
English: What was Veraflox to be used for?
Estonian: Milleks kavatseti Verafloxi kasutada?
English: Pradofloxacin is an antibiotic.
Estonian: Pradofloksatsiin on antibiootikum.
English: Veraflox Oral Suspension was to be used for the treatment of cats with acute infections of the upper respiratory tract and also some skin conditions caused by certain specific bacteria.
Estonian: Verafloxi suukaudset suspensiooni kavatseti kassidel kasutada teatavate bakterite põhjustatud ülemiste hingamisteede ägedate infektsioonide ja ka teatavate nahahaiguste ravimiseks.
English: In cats, the medicine was studied in acute infections of the upper respiratory tract and also some skin conditions caused by certain specific bacteria.
Estonian: Kassidel uuriti ravimi kasutamist teatavate bakterite põhjustatud ülemiste hingamisteede ägedate infektsioonide ja ka teatavate nahahaiguste ravimiseks.
English: In cats, Veraflox Tablets were to be used for the treatment of acute infections of the upper respiratory tract caused by certain specific bacteria.
Estonian: Kassidel kavatseti Verafloxi tablette kasutada teatavate bakterite põhjustatud ülemiste hingamisteede ägedate infektsioonide ravimiseks.
English: In dogs, Veraflox Tablets were to be used for the treatment of skin, urinary tract and gum infections caused by certain specific bacteria.
Estonian: Verafloxi tablette kavatseti kasutada koertel teatavate bakterite põhjustatud naha, kuseteede ja igemete infektsioonide ravimiseks.
English: A European Commission issued a decision on 27 July 2010.
Estonian: Euroopa Komisjon tegi otsuse 27. juulil 2010.
English: Medicines containing bufexamac have been authorised in Austria, Bulgaria, the Czech Republic, France, Hungary, Italy, Latvia, Lithuania, Luxembourg, Portugal, Romania and Slovakia.
Estonian: Bufeksamakki sisaldavad ravimid on heaks kiidetud Austrias, Bulgaarias, Itaalias, Leedus, Luksemburgis, Lätis, Portugalis, Prantsusmaal, Rumeenias, Slovakkias, Tšehhi Vabariigis ja Ungaris.
English: • Patients who have any questions should speak to their doctor or pharmacist.
Estonian: • Patsiendid, kel on mis tahes küsimusi, peavad pöörduma oma arsti või apteekri poole.
English: The allergic reactions can be serious enough to require hospitalisation.
Estonian: Allergiareaktsioonid võivad olla piisavalt rasked, et nõuda haiglaravi.
English: Furthermore, because these reactions are very similar to the disease being treated, it can lead to delays in the diagnosis or treatment of the patient's condition.
Estonian: Et need reaktsioonid on väga sarnased ravitava haigusega, siis võib tekkida viivitusi patsiendi haiguse diagnoosimisel või ravimisel.
English: Procedure start date:
Estonian: Menetluse alustamise kuupäev:
English: Most of the studies dated from the original development of bufexamac in the 1970s and 1980s, and were of a lower standard than that expected today.
Estonian: Suurem osa uuringuid oli tehtud bufeksamaki väljatöötamise ajal 1970. ja 1980. aastatel ning nende standard oli madalam kui peetakse vajalikuks tänapäeval.
English: Why was bufexamac reviewed?
Estonian: Miks bufeksamaki andmed uuesti üle vaadati?
English: What is bufexamac?
Estonian: Mis on bufeksamak?
English: • Doctors should stop prescribing medicines containing bufexamac.
Estonian: • Arstid peavad lõpetama bufeksamakki sisaldavate ravimite määramise.
English: The Committee noted that the data presented to support the effectiveness of bufexamac were very limited.
Estonian: Komitee märkis, et bufeksamaki efektiivsuse toetuseks esitatud andmete hulk oli väga piiratud.
English: The CHMP noted that bufexamac-containing medicines have been available since the 1970s, and that contact allergic reactions have been reported over the years, leading to restrictions on the use of the medicines in a number of countries.
Estonian: Inimravimite komitee märkis, et bufeksamakki sisaldavaid ravimeid turustatakse alates 1970. aastatest ja et aastate jooksul on teatatud kontaktallergiareaktsioonidest, mistõttu on nende ravimite kasutamist piiratud mitmes riigis.
English: They may be available as creams, rectal ointments and suppositories, and under the following invented names: Parfenac, Bufal, Calmaderm, Fansamac, Mastu S, Parfenoide, Proctosan, and other trade names.
Estonian: Neid ravimeid turustatakse kreemi, rektaalsalvi ja rektaalsuposiidina järgmiste kaubanduslike nimetuste all: Parfenac, Bufal, Calmaderm, Fansamac, Mastu S, Parfenoide, Proctosan jt.
English: It is also likely that the difficulty to differentiate between a treatment failure and an allergic reaction has led to the cases of contact allergic reaction being underreported.
Estonian: Samuti on tõenäoline, et kuna ravivastuse puudumist ja allergilist reaktsiooni on raske eristada, siis võidakse kontaktallergiareaktsioone teatada tegelikkusest vähem.
English: • Patients currently using bufexamac-containing medicines should speak to their doctor so they can switch to an appropriate alternative treatment.
Estonian: • Bufeksamakki sisaldavaid ravimeid kasutavad patsiendid peavad pöörduma oma arsti poole, et saada sobivat muud ravi.
English: The European Medicines Agency has completed a review of the safety and effectiveness of bufexamac.
Estonian: Euroopa Ravimiamet (EMA) on lõpetanud bufeksamaki ohutuse ja efektiivsuse andmete läbivaatamise.
English: Because of this, no evidence of the effectiveness of bufexamac could be derived from them.
Estonian: Seetõttu ei olnud võimalik saada nendest bufeksamaki efektiivsuse tõendeid.
English: 27 July 2010
Estonian: 27. juuli 2010
English: As required by Article 107, the agency informed the CHMP of its action so that the Committee could prepare an opinion on whether the marketing authorisations for products containing bufexamac should be maintained, changed, suspended or revoked across the EU.
Estonian: Artikli 107 kohaselt teatas Saksamaa ravimiamet inimravimite komiteele oma tegevusest, et komitee saaks ette valmistada arvamuse selle kohta, kas bufeksamakki sisaldavate ravimite müügiload tuleb kogu Euroopa Liidus jätta jõusse, kas neid tuleb muuta, kas need tuleb peatada või tühistada.
English: The risk of developing a contact allergic reaction to bufexamac is high, and the risk is even higher in patients with pre-disposing conditions, such as certain forms of eczema, for which bufexamac is frequently prescribed.
Estonian: Bufeksamakiga seotud kontaktallergiareaktsiooni tekke risk on suur, eriti suur on see patsientidel, kellel on eelsoodumuslikke seisundeid (nt teatud tüüpi ekseemid), mille korral määratakse sageli bufeksamaki ravi.
English: In particular, the Committee considered the responses given by the companies to a list of questions on allergic reactions reported following contact with bufexamac.
Estonian: Komitee võttis arvesse eelkõige ettevõtete vastuseid küsimustele, mis käsitlesid pärast kokkupuudet bufeksamakiga tekkinud allergiareaktsioone.
English: Bufexamac is used to control the symptoms of inflammation of the skin (such as redness and itching) in diseases such as eczema and dermatitis.
Estonian: Bufeksamakki kasutatakse naha põletikusümptomite (nt punetuse ja sügeluse) leevendamiseks näiteks ekseemi ja dermatiidi korral.
English: Bufexamac is a non-steroidal anti-inflammatory drug (NSAID).
Estonian: Bufeksamak on mittesteroidne põletikuvastane ravim (NSAID).
English: During this review, the agency obtained information from the companies marketing bufexamac in Germany, and looked at published studies on the effectiveness of bufexamac.
Estonian: Läbivaatamise käigus sai asutus andmeid Saksamaal bufeksamakki turustavatelt ettevõtetelt ja tutvus bufeksamaki efektiivsuse avaldatud uuringutega.
English: The CHMP also noted that bufexamac is a ‘sensitizer' causing reactions to get worse with repeated exposure.
Estonian: Samuti märkis inimravimite komitee, et bufeksamak on ülitundlikkust tekitav aine, mille korduval kasutamisel muutuvad reaktsioonid järjest raskemaks.
English: In December 2009, the German medicines regulatory agency completed a review of the benefits and risks of bufexamac-containing medicines.
Estonian: Saksamaa ravimiamet lõpetas 2009. aasta detsembris bufeksamakki sisaldavate ravimite kasulikkuse ja riski andmete läbivaatamise.